Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?
Capricor Therapeutics, Inc. (NASDAQ: CAPR) surged 58% on August 14 after the FDA agreed to review an amendment containing 24-month data for its Duchenne muscular dystrophy treatment, deramiocel. The stock had previously climbed 94% above its previous close before pulling back. The approval remains uncertain, as the FDA did not change its decision date, and the amendment may extend review time by about three months.
The FDA raised concerns about analytical changes, missing data, measurement uncertainty, and whether patients with normal heart function at baseline represented the cardiomyopathy population. Capricor's SAP 3.0 analysis showed a p-value of 0.029 for the upper-limb endpoint, though the FDA used the original analysis methodology and obtained a p-value of 0.24.
The proposed 24-month evidence comes from an open-label extension, which cannot provide a randomized, placebo-controlled comparison. Despite the rebound, the concentration risk remains high, with the company having no first-half revenue, $42.9 million in second-quarter operating expenses, and facing a distribution dispute with NS Pharma.
The FDA's willingness to consider additional evidence has indeed reduced the risk of an immediate rejection, but the rally did not resolve the disagreement over Capricor's statistical methodology or provide a controlled 24-month comparison.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.